Additionally, data on most recent cardiovascular drugs for HF (e.g. sacubitril/valsartan and sodium glucose cotransporter 2 (SGLT2)-inhibitors), treatment adherence and efficacy (e.g. reaching of glycaemic target) were not available, and this poses some limitations to our results. The gene discussed is SLC5A2; the disease is hydrops fetalis.